Related Experiment Video
Updated: Jul 5, 2026

Whole Genome Sequencing of Candida glabrata for Detection of Markers of Antifungal Drug Resistance
Published on: December 28, 2017
[Anidulafungin: a new echinocandin for the treatment of mycosis]
1Servicio de Microbiología, Unidad de Micología, Hospital Universitario 12 de Octubre, Madrid, Spain. apalacioh.hdoc@salud.madrid.org
Abstract:
The latest antifungal drugs introduced for clinical use are echinocandins; they possess a distinctive mechanism of action based on the inhibition of the beta-1,3-D-glucan sintesis, through the damage of the fungal cell wall without impairment of human cells because these do not contain beta-1,3-D-glucan. Among echinocandins, anidulafungin is the last that has received the FDA approval in the USA for the treatment of candidemia in non-neutropenic patients, intra-abdominal abscesses, peritonitis and esofagitis caused by Candida. In Europe, the EMEA has also approved its use for invasive candidiasis in non-neutropenic patients and for candidal esofagitis. The characteristics of anidulafungin are close to those of the ideal antifungal since it has a wide spectrum, is active at low minimal inhibitory concentrations and it is fungicidal for Candida. In addition, it is well tolerated, has few pharmacological interactions, is active intravenously, has a long half life and is auto-biodegradable. Finally, anidulafungin has shown a higher therapeutic efficiency when compared with the conventional treatment of candidemia, since although it is more expensive, the treatment with anidulafungin is highly cost effective.
Related Concept Videos
Antifungal Agents
Anthelminthic Agents
Cryptococcal Meningitis
Candidiasis
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions
Fungal Phylum Microsporidia
